PPARγ ligand treatment inhibits cardiac inflammatory mediators induced by infection with different lethality strains of Trypanosoma cruzi.
Trypanosoma cruzi (T. cruzi), the etiological agent of Chagas' disease, causes cardiac alterations in the host. Although the main clinical manifestations arise during the chronic stage, the mechanisms leading to heart damage develop early during infection. In fact, an intense inflammatory response is observed from acute stage of infection. Recently, peroxisome proliferator-activated receptors (PPARs) have attracted research interest due to their participation in the modulation of inflammation. In this work we addressed the role of 15-Deoxy-∆(12,14) ProstaglandinJ2 (15dPGJ2), a PPARγ natural ligand in the regulation of inflammatory mediators, in acute and chronic experimental mouse models of Chagas' disease with the RA and K98 T. cruzi strains, respectively. This work demonstrates that 15dPGJ2 treatment inhibits the expression and activity of inducible nitric oxide synthase (NOS2) as well as TNF-α and IL-6 mRNA levels. Also, expression and activity of metalloproteinases 2 (MMP-2) and 9 (MMP9) were inhibited by 15dPGJ2. Moreover GW9662, a specific PPARγ antagonist, revealed the participation of other signaling pathways since, in GW9662 presence, 15dPJG2 had a partial effect on the inhibition of inflammatory parameters in the acute model of infection. Accordingly, NF-κB activation was demonstrated, assessing p65 nuclear translocation in the hearts of infected mice with both T. cruzi strains. Such effect was inhibited after 15dPGJ2 treatment. Our findings support the concept that in vivo PPARγ and NF-κB pathways are implicated in the inhibitory effects of 15dPGJ2 on inflammatory mediators at different times depending on whether the infection is caused by the lethal or non-lethal T. cruzi strain.
Instituto de Microbiología y Parasitología Médica, Buenos Aires, Argentina.
Federico
F
Penas
Gerardo A
GA
Mirkin
Eugenia
E
Hovsepian
Agata
A
Cevey
Roberto
R
Caccuri
María Elena
ME
Sales
Nora B
NB
Goren
D000818:Animals; D014355:Chagas Disease / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology* / Q000469:parasitology; D015536:Down-Regulation / Q000187:drug effects; D006321:Heart / Q000187:drug effects; D006801:Humans; D018836:Inflammation Mediators / Q000276:immunology*; D015850:Interleukin-6 / Q000235:genetics / Q000276:immunology; D008024:Ligands; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009206:Myocardium / Q000276:immunology*; D052247:Nitric Oxide Synthase Type II / Q000235:genetics / Q000276:immunology; D047495:PPAR gamma / Q000235:genetics / Q000276:immunology; D015230:Prostaglandin D2 / Q000008:administration & dosage*; D014349:Trypanosoma cruzi / Q000472:pathogenicity / Q000502:physiology*; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000276:immunology
D018836:Inflammation Mediators; D015850:Interleukin-6; D008024:Ligands; D047495:PPAR gamma; D014409:Tumor Necrosis Factor-alpha; D052247:Nitric Oxide Synthase Type II; D015230:Prostaglandin D2